<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathophysiology of thalassemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathophysiology of thalassemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathophysiology of thalassemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward J Benz, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elliott P Vichinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Alpha and beta thalassemia are inherited hemoglobinopathies in which impaired production of one type of globin chain (alpha chains in alpha thalassemia; beta chains in beta thalassemia) causes an imbalance in the ratio between alpha and beta (or beta-like) chains, which is normally tightly controlled. </p><p>Balanced synthesis is important because the intact hemoglobin A (Hb A) and hemoglobin F (Hb F) tetramers are highly soluble in red blood cell (RBC) cytoplasm, but the unbound alpha and beta chains are not. They precipitate, causing significant cellular damage. These unpaired chains cause problems with RBC maturation and lead to ineffective erythropoiesis, hemolytic anemia, iron overload, and ensuing complications.</p><p>This topic discusses the pathophysiology of alpha and beta thalassemia. Separate topic reviews discuss: </p><p class="bulletIndent1"><span class="glyph">●</span>Genetics – (See  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing – (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations and diagnosis – (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management – (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a> and  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematopoietic stem cell transplant – (See  <a class="medical medical_review" href="/d/html/3554.html" rel="external">"Hematopoietic stem cell transplantation for transfusion-dependent thalassemia"</a> and  <a class="medical medical_review" href="/d/html/3555.html" rel="external">"Thalassemia: Management after hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY AND DISEASE CLASSIFICATION</span><span class="headingEndMark"> — </span>Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains  (<a class="graphic graphic_table graphicRef115337" href="/d/graphic/115337.html" rel="external">table 1</a>). This can lead to a relative excess of unpaired chains from the unaffected genes, which continue to be produced at normal rates.</p><p class="headingAnchor" id="H3424591420"><span class="h2">Beta thalassemia</span><span class="headingEndMark"> — </span>Beta thalassemia is caused by variants (mutations) in the hemoglobin beta locus (<em>HBB</em>, beta globin gene) that lead to impaired production of beta globin chains. This leads to an excess of alpha or alpha-type chains. </p><p>Beta<sup>0</sup> variants are those that abolish beta globin production, and beta<sup>+</sup> variants can produce some beta globin but far less than the normal amount. The clinical phenotype depends on which combination of beta globin variants an individual carries.</p><p>Previously, individuals with beta thalassemia were classified (in order of decreasing severity) as having beta thalassemia major, intermedia, and minor. Subsequent classification has shifted to use of the terms transfusion dependent and non-transfusion dependent. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Overview of subtypes and disease severity'</a>.) </p><p>The new terminology has been adopted because it is based on the clinical status of the patient with regard to a major prognostic feature (lifelong transfusion dependence, or not) and cleanly distinguishes these two groups of patients. In contrast, the category called thalassemia intermedia was deemed too broad and vague, ranging from minimal symptomatology to clinical stigmata overlapping with severe transfusion-dependent beta thalassemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-dependent</strong> – Transfusion-dependent individuals require regular transfusions to mitigate severe anemia and extramedullary hematopoiesis. These individuals were previously referred to as having beta thalassemia major. Individuals who periodically require transfusions for anemia are not considered transfusion dependent, but they may become so over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-transfusion-dependent</strong> – Non-transfusion-dependent individuals do not require regular transfusions. They may never receive a transfusion, or they may periodically require transfusions for anemia (eg, during pregnancy or an acute infection). These individuals were described as having thalassemia intermedia if anemic and/or showing stigmata of hemolytic anemia or ineffective erythropoiesis, and as having thalassemia minor if minimally symptomatic. However, the term thalassemia minor was also used to describe the almost universally asymptomatic heterozygous state. This confusion was an additional reason for transitioning to the new terminology.</p><p></p><p>Every individual has two beta globin genes (one from each parent). Beta thalassemia gene variants are classified according to the degree of reduction in beta globin production  (<a class="graphic graphic_table graphicRef115337" href="/d/graphic/115337.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Beta<sup>0</sup> thalassemia refers to pathogenic gene variants that completely abolish beta globin production. Patients who are homozygous or compound heterozygous for beta<sup>0</sup> thalassemia mutations are more likely to have transfusion-dependent beta thalassemia (previously called beta thalassemia major); they cannot make any beta globin chains and hence cannot make the normal adult hemoglobin (hemoglobin A [Hb A]; alpha2/beta2). These are the patients originally described by Cooley. They often have profound, transfusion-dependent anemia and other manifestations of severe thalassemia. Individuals heterozygous for beta<sup>0</sup> thalassemia are more likely to have a lower hemoglobin, and a few may even exhibit mild stigmata of hemolysis and ineffective erythropoiesis. </p><p></p><p class="bulletIndent1">There are exceptions to this general trend, and beta<sup>0</sup> thalassemia patients can be non-transfusion-dependent. For example, some mutations abolishing beta globin synthesis, such as delta beta thalassemia (also called Hb Lepore syndrome) are associated with significant compensatory production of gamma chains, and therefore, fetal hemoglobin (Hb F) in post-natal life. Coinheritance of alpha thalassemia trait can also reduce chain imbalance, thereby reducing severity. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta<sup>+</sup> thalassemia refers to mutations that cause decreased (but not absent) beta globin production. Patients who are homozygous for beta<sup>+</sup> thalassemia mutations can make some Hb A and tend to be less severely affected than those with beta<sup>0</sup> thalassemia mutations. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with a beta<sup>+</sup> thalassemia mutation combined with a beta<sup>0</sup> thalassemia mutation typically have transfusion-dependent beta thalassemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with two beta<sup>+</sup> thalassemia mutations typically have transfusion-independent beta thalassemia, although some may be transfusion dependent or may become transfusion dependent later in life. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals heterozygous for beta<sup>+</sup> thalassemia inherit a beta thalassemia allele from one parent and a normal beta globin allele from the other parent. These individuals have profound microcytosis but mild or minimal anemia; they are largely asymptomatic and are often identified incidentally (by family testing or on a complete blood count [CBC] done for other reasons). Anemia can become more significant during pregnancy.</p><p></p><p>The beta thalassemia mutations are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.)</p><p class="headingAnchor" id="H1866561299"><span class="h2">Alpha thalassemia</span><span class="headingEndMark"> — </span>Alpha thalassemia is caused by pathogenic gene variants in the hemoglobin alpha locus (alpha globin genes) that lead to impaired production of alpha globin chains  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). This results in a relative excess of beta and beta-like chains. Depending largely on the alpha globin genotype, individuals with symptomatic alpha thalassemia can either be transfusion independent (common) or transfusion dependent (rare).</p><p>Alpha<sup>0</sup> variants are those that abolish alpha globin production, and alpha<sup>+</sup> variants can produce some alpha globin but less than the normal amount. Often alpha<sup>0</sup> variants are those in which an entire alpha globin gene cluster is deleted (deletional variants) whereas alpha<sup>+</sup> variants may involve point mutations (non-deletional variants). The most common non-deletional alpha globin variant is hemoglobin Constant Spring. (See  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.) </p><p>In contrast to beta thalassemias, in which beta<sup>+</sup> variants tend to be less severe, some alpha<sup>+</sup> alleles such as Hb Constant Spring can actually aggravate severity. This is because the common alpha<sup>+</sup> alleles encode alpha chains that, when combined with beta chains, create highly unstable hemoglobins that precipitate, adding to the burden of inclusion bodies in the developing and circulating RBCs.</p><p>The alpha globin gene cluster has two copies of the alpha globin gene, alpha2 and alpha1. Thus, every individual has four alpha globin genes (two from each parent); the designation "aa/aa" is used to describe four normally functioning alpha globin genes. The clinical phenotype depends on which combination of alpha globin variants an individual carries. There are multiple possible combinations of variants, increasing the complexity of alpha thalassemia classification.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydrops fetalis with Hb Barts</strong> – The syndrome of hydrops fetalis is the most severe form of alpha thalassemia, due to deletion or inactivation of all four alpha globin genes (--/--). This syndrome was previously considered to be incompatible with live birth, due to lack of alpha chains that normally appear after the fifth or sixth week of fetal life. However, live births have been reported with antenatal diagnosis and in-utero transfusions, in some cases followed by allogeneic bone marrow transplantation [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/131582.html" rel="external">"Alpha thalassemia major: Prenatal and postnatal management"</a>.)</p><p></p><p class="bulletIndent1">Normal fetal hemoglobin (Hb F) is a tetramer of alpha chains and gamma chains. In the absence of functional alpha chains, gamma chains homotetramerize to form hemoglobin Barts (Hb Barts). Hb Barts has little propensity to precipitate and form inclusions [<a href="#rid3">3</a>]. However, Hb Barts (as well as homotetramers of beta globin; hemoglobin H [Hb H]) are functionally useless for oxygen delivery due to their high affinity for oxygen (10 times greater than that of Hb A); they are susceptible to oxidant injury [<a href="#rid4">4,5</a>]. They demonstrate no Bohr effect, and they lack a sigmoidal hemoglobin-oxygen dissociation curve due to lack of heme-heme interaction. Instead, their oxyhemoglobin dissociation curves resemble that of myoglobin [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p></p><p class="bulletIndent1">Zeta chains are an embryonic alpha-like chain. If the genetic variant allows the fetus to synthesize zeta chains, then hemoglobin Portland (Hb Portland; zeta2 gamma2) can be produced, allowing survival in utero until the third trimester [<a href="#rid7">7</a>]. These fetuses are functionally severely anemic, with high-output cardiac failure, anasarca, and capillary leak ("hydrops"), along with enlarged placenta and maternal hypertension and polyhydramnios, despite the fact that the measured hemoglobin concentration may be as high as 10 g/dL due to the presence of Hb Barts and Hb Portland (see  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis"</a>). The red blood cells (RBCs) are hypochromic and microcytic, and erythropoiesis is vastly expanded to compensate for the resulting profound tissue hypoxia, with compensatory extramedullary erythropoiesis in the liver and spleen. A small component of Hb H may also be present in the late stages of gestation, when the fetus begins to synthesize small amounts of beta chains. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Embryonic hemoglobins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb H disease</strong> – Hb H disease refers to deletion or inactivation of three of the four alpha globin genes (a-/--). Clinically significant unbalanced globin chain synthesis, with an alpha/beta synthesis ratio of 0.3 to 0.6 (normal, 1.0±0.05), causes accumulation of unpaired gamma chains during fetal development and early infancy and accumulation of unpaired beta chains in adulthood [<a href="#rid8">8,9</a>]. </p><p></p><p class="bulletIndent1">The resulting gamma globin homotetramers in the fetus and infant form Hb Barts, and the resulting beta globin homotetramers in the child and adult form Hb H [<a href="#rid4">4,10,11</a>]. As noted above, Hb Barts and Hb H are functionally useless for oxygen delivery. However, the presence of one functioning alpha globin allele supports enough Hb F synthesis to allow the fetus to survive gestation and enough Hb A synthesis to sustain postnatal life, albeit with significant morbidity. </p><p></p><p class="bulletIndent1">Hb H disease was identified simultaneously by two groups of investigators in 1955 [<a href="#rid12">12,13</a>]. Affected patients had a hypochromic microcytic anemia of variable severity; target cells on peripheral smear; reticulocytosis; inclusions in a few red blood cells (RBCs) known as Heinz bodies, many more of which could be produced by incubating RBCs with mild oxidant dyes like brilliant cresyl blue, resistance to lysis by hypotonic solutions, and signs of hemolysis, including a shortened <sup>51</sup>Cr RBC survival, splenomegaly, and elevated indirect reacting bilirubin. (See  <a class="medical medical_review" href="/d/html/7082.html" rel="external">"Red blood cell survival: Normal values and measurement"</a>.)</p><p></p><p class="bulletIndent1">A key finding was the presence of an abnormal hemoglobin, accounting for up to 40 percent of the total hemoglobin, which had more rapid electrophoretic mobility at pH 8.6 than Hb A  (<a class="graphic graphic_figure graphicRef50325" href="/d/graphic/50325.html" rel="external">figure 2</a>). Upon standing, Hb H turned brown and precipitated, forming aggregates that looked somewhat like the RBC inclusions, a phenomenon accentuated by the addition of mild oxidants.</p><p></p><p class="bulletIndent1">In deletional Hb H disease, the patient has inherited only a single alpha globin gene (a-/--). In the non-deletional form, the patient has inherited two alpha globin genes from one parent, but one of these carries a non-deletional defect such as a point mutation (aa*/--, where a* represents a variant such as hemoglobin Constant Spring). The most common alpha<sup>+</sup> mutations generate highly unstable hemoglobins, which add to the inclusion body burden of the RBCs [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/7086.html" rel="external">"Unstable hemoglobin variants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha thalassemia minor/trait</strong> – Inheritance of two normal and two deletional alpha genes, referred to as alpha thalassemia minor or alpha thalassemia-1 trait, can occur with heterozygosity for an alpha<sup>0</sup> genotype (aa/--) or heterozygosity for an alpha<sup>+</sup> genotype (a-/a-). These individuals have minimal or no anemia and microcytosis (low mean corpuscular volume [MCV]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha thalassemia minima/silent carrier</strong> – Inheritance of three normal and one deletional alpha genes (aa/a-) is referred to as alpha thalassemia minima, silent carrier, or alpha thalassemia-2 trait. These individuals often have no clinical or hematologic abnormalities. The diagnosis can be reliably made only via DNA analysis. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Molecular genetic (DNA-based) methods'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complex alpha thalassemia</strong> <strong>variants</strong> – In addition to the variants described above, individuals can have alpha<sup>0</sup> variants from one parent and alpha<sup>+</sup> variants from the other parent. </p><p></p><p class="headingAnchor" id="H2174525123"><span class="h2">Combinations of hemoglobin variants</span><span class="headingEndMark"> — </span>Further complexity occurs when an individual carries combinations of alpha and beta globin gene variants, or combinations of alpha or beta thalassemia with another hemoglobin variant such as sickle hemoglobin or Hb C.</p><p>As a general rule, alpha thalassemia plus a beta globin variant tends to partially ameliorate the severity of the beta globin variant, whereas beta thalassemia plus a beta globin variant like Hb S tends to produce the clinical phenotype of the other variant, which is frequently slightly milder (sickle-beta thalassemia) because the thalassemia allele lowers the intracellular concentration of hemoglobin, which reduces sickling. </p><p>Some structural variants are also associated with reduced globin biosynthesis (eg, Hb E, listed below) or accumulation due to instability (eg, Hb Terra Haute), in which case, coinheritance of a beta thalassemia allele aggravates the clinical phenotype.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha and beta thalassemia</strong> – Individuals with coinheritance of homozygous beta<sup>+</sup> thalassemia (beta<sup>+</sup>/beta<sup>+</sup>) and alpha thalassemia (-a/-a, --/aa, or -a/aa) will present with intermediate clinical severity. The concomitant reduction of both alpha and beta chains reduces the degree of imbalance relative to what would occur if only one or the other type of chain was affected. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary persistence of fetal hemoglobin</strong> – Certain beta globin variants lead to production of higher levels of Hb F, which can serve as a beta globin-like partner with alpha globin, leading to a less severe imbalance in the alpha-to-beta globin ratio in individuals with beta thalassemia  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hereditary persistence of fetal hemoglobin (HPFH)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sickle-beta thalassemia</strong> – Co-inheritance of the sickle mutation on one beta globin allele and a thalassemic mutation at the other beta globin allele leads to sickle cell disease, the severity of which depends on the nature of the beta thalassemic mutation (ie, whether it results in reduced [beta<sup>+</sup>] or absent [beta<sup>0</sup>] beta globin production). (See  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes", section on 'Sickle-beta thalassemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb E</strong> – Hb E results from a beta globin mutation that reduces beta globin production. Compound heterozygosity for Hb E and a beta thalassemia variant is responsible for a large proportion of severe beta thalassemia throughout the world [<a href="#rid16">16</a>]. It occurs at a frequency of 3 to 9 percent in Thailand [<a href="#rid17">17,18</a>]. The clinical phenotype is heterogeneous, with hemoglobin levels ranging from approximately 3 to 14 g/dL; the co-inheritance of an alpha thalassemia variant may modulate the phenotype [<a href="#rid16">16</a>]. Hb E is commonly seen in India and Southeast Asia. The phenotype appears to be especially severe in Sri Lanka [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dominant thalassemia</strong> – Dominant thalassemia refers to several single rare beta thalassemia variants that produce a disease picture in the heterozygous state typically characterized by a non-transfusion-dependent (NTD) beta thalassemia intermedia phenotype and occasionally a transfusion-dependent clinical picture [<a href="#rid20">20</a>]. These autosomal dominant variants are often missense mutations in exon 3 that produce unstable and hyper-unstable globins. These dominant beta thalassemia variants have often been described as de novo mutations in families of dispersed ethnic origins. The majority of cases are not detected by conventional testing, and they therefore require increased clinical awareness and specialized testing. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a>.)</p><p></p><p>The clinical phenotype cannot be completely predicted from the globin genotype, as other genetic variation and environmental factors can influence disease severity. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a> and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes", section on 'Sickle-beta thalassemia'</a> and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes", section on 'Sickle-alpha thalassemia'</a>.)</p><p class="headingAnchor" id="H2525809067"><span class="h2">Acquired alpha thalassemia in MDS</span><span class="headingEndMark"> — </span>Individuals with clonal hematopoietic disorders such as myelodysplastic syndrome (MDS) can develop acquired alpha thalassemia in the clonal population; this is also referred to as acquired Hb H disease. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Acquired hemoglobin H disease'</a>.)</p><p class="headingAnchor" id="H3357829926"><span class="h1">GLOBIN CHAIN IMBALANCE</span><span class="headingEndMark"> — </span>Hemoglobin is a tetramer consisting of two heterodimers; each heterodimer has one alpha globin-like chain and one beta globin-like chain (as well as heme). The ratio of alpha- to beta-like globin chains is tightly controlled at 1.00±0.05. </p><p>Gene variants in thalassemia disrupt this normal regulation by producing reduced levels of one of the types of globin chains [<a href="#rid21">21,22</a>]. The free (unpaired) alpha or beta chains cannot be incorporated into normal hemoglobin A (Hb A; alpha-beta tetramers). Beta globin production begins at approximately the 35<sup>th</sup> to 38<sup>th</sup> weeks of gestation and abruptly increases after birth, so that Hb A predominates by approximately six months postnatally. Alpha globin production begins early in fetal development (approximately six weeks of gestation) and persists at high levels throughout life. </p><p>Differing properties of alpha and beta chains and their effects on developing red blood cells (RBCs) are summarized in the table  (<a class="graphic graphic_table graphicRef130100" href="/d/graphic/130100.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta thalassemia</strong> – For reasons that are not entirely clear, excess alpha globin chains cannot form soluble homotetramers. They are unstable and begin aggregating as soon as they accumulate in erythroid precursors, producing insoluble aggregates that precipitate adjacent to the RBC membrane [<a href="#rid23">23</a>]. This occurs in very early marrow erythroid precursors, affecting membrane assembly and accelerating programmed cell death. </p><p></p><p class="bulletIndent1">A different beta-like chain (also called "non-alpha" chain) is used during fetal development and early childhood. The switching between beta-like chains  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>) is controlled by a complex set of enhancer and silencer sequences (elements) near the gene loci, along with their cognate transcription factors. These have become targets for therapeutic manipulation to increase postnatal Hb F synthesis in beta chain hemoglobinopathies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Embryo – Epsilon chains</p><p class="bulletIndent2"><span class="glyph">•</span>Fetus and neonate – Gamma chains</p><p class="bulletIndent2"><span class="glyph">•</span>Young child through adult – Beta chains (plus a minor component of delta chains, which form Hb A2)</p><p></p><p class="bulletIndent1">Since beta thalassemia mutations affect beta chains but not embryonic (epsilon) or fetal (gamma) chains, the age of onset of beta thalassemia is in early childhood rather than during fetal development. Symptoms emerge only when Hb F is replaced by adult hemoglobin following the perinatal Hb F to Hb A switch  (<a class="graphic graphic_figure graphicRef109086" href="/d/graphic/109086.html" rel="external">figure 3</a>). </p><p></p><p class="bulletIndent1">Some individuals have triplication of alpha globin genes. A case report of three individuals with beta thalassemia and a simultaneous triplication of the alpha globin gene (encoding six rather than four alpha globin chains) described strong enhancement of the beta thalassemia phenotype, further supporting the correlation between the degree of chain imbalance with clinical severity [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">Conversely, as noted above, coinheritance of an alpha thalassemia variant that reduces alpha chain production in an individual with beta thalassemia results in a less severe phenotype by shifting the ratio of alpha to beta globin closer to 1. (See <a class="local">'Combinations of hemoglobin variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha thalassemia</strong> – In alpha thalassemia, excess beta-like chains can form somewhat soluble tetramers. They do not produce a major inclusion body burden in early- to mid-stage erythroblasts. Ineffective erythropoiesis is thus less marked in most alpha thalassemia patients (relative to beta thalassemia patients). In the fetus and infant, these are predominantly gamma globin tetramers (Hb Barts); in the child and adult, they are predominantly beta globin tetramers (Hb H). </p><p></p><p class="bulletIndent1">Since alpha chains are required to produce functional hemoglobins during fetal development, alpha thalassemia manifests before birth. Homozygous alpha<sup>0</sup> thalassemia is generally considered to be incompatible with extrauterine life, with rare exceptions involving intrauterine transfusions. (See  <a class="medical medical_review" href="/d/html/131582.html" rel="external">"Alpha thalassemia major: Prenatal and postnatal management"</a>.)</p><p></p><p class="bulletIndent1">In individuals with a form of alpha thalassemia caused by the Constant Spring variant (CS) hemoglobin, an increase in ineffective erythropoiesis is probably due to the binding of unstable precipitates of alpha CS, in addition to beta chains, to the membranes of erythroid precursors. </p><p></p><p>Globin chain imbalance and the resulting unpaired globin chains have a number of effects on the structure and mechanical properties of RBCs. (See <a class="local">'Effects on the RBC'</a> below.)</p><p class="headingAnchor" id="H3122094319"><span class="h1">EFFECTS ON THE RBC</span></p><p class="headingAnchor" id="H2314603833"><span class="h2">Oxidative injury</span><span class="headingEndMark"> — </span>Oxidation is a normal phenomenon in red blood cells (RBCs; hemoglobin is oxidized to methemoglobin at a rate of approximately 0.5 to 3 percent per day); however, in normal RBCs, the oxidized methemoglobin subsequently is reduced (restored to native hemoglobin) via cytochrome b5 reductase [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'How are the levels regulated?'</a>.)</p><p>In thalassemic RBCs, unpaired alpha or beta chains with an attached heme moiety are susceptible to oxidation. They are partly proteolyzed to form hemichromes (oxidized and partly catabolized peptide fragments) [<a href="#rid26">26-28</a>]. These iron-containing hemichromes can generate reactive oxygen species (ROS), perhaps by acting as Fenton reagents; in turn they can oxidize adjacent RBC membrane proteins and lipids [<a href="#rid29">29-32</a>]. </p><p>Oxidant injury can damage RBC membranes indirectly, by affecting globin chains that bind to the membranes, or by directly altering cytoskeletal or integral membrane proteins, as evidenced by loss of free thiols within globin chains and other membrane proteins [<a href="#rid33">33-36</a>]. Oxidant injury to membrane proteins and lipids can have profound effects on membrane properties. (See <a class="local">'Membrane damage'</a> below.)</p><p>Oxidant injury is in turn worsened by free iron, levels of which are in turn increased by the effects of oxidant injury [<a href="#rid37">37</a>] (see <a class="local">'Iron overload'</a> below). Increased amounts of membrane iron have been found in association with denatured hemoglobin in beta thalassemic cells [<a href="#rid38">38</a>]. Proteolysis of some cytoskeletal and membrane proteins may also occur, although this has not been studied directly. </p><p>In vitro incubation of thalassemic RBCs with mild oxidants such as <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a> and brilliant cresyl blue can enhance hemichrome formation [<a href="#rid12">12,13</a>]. This allows one to visualize these precipitated, mutilated remnants of globin, which have been termed "inclusion bodies." A clinical counterpart is the observation that hemolysis may be exacerbated when individuals with hemoglobin H (Hb H) disease are exposed to oxidant drugs, such as the sulfonamides, or to conditions that predispose to oxidative stress, such as infections [<a href="#rid5">5</a>]. In this sense, Hb H mimics many of the clinical features of unstable hemoglobins. (See  <a class="medical medical_review" href="/d/html/7086.html" rel="external">"Unstable hemoglobin variants", section on 'Clinical manifestations'</a>.)</p><p>In experiments designed to model the oxidant damage, normal RBCs were incubated with the oxidant compounds methylhydrazine (MHZ) and phenylhydrazine (PHZ) [<a href="#rid39">39</a>]. MHZ induced the binding of oxidized beta globin chains to the membrane skeleton, and the membranes became hyperstable, as is typical for severe alpha thalassemia. In contrast, PHZ induced the binding of oxidized alpha globin chains to the membrane skeleton, causing them to become unstable, exactly as seen in the RBCs in severe beta thalassemia. (See <a class="local">'Membrane damage'</a> below.) </p><p>High levels of oxidant stress in thalassemic RBCs is further supported by findings of decreased hexose monophosphate shunt activity, a source of protection against oxidant injury, and increased superoxide dismutase, glutathione peroxidase, catalase, and other enzymes important in oxidant defense [<a href="#rid40">40-42</a>].</p><p class="headingAnchor" id="H4116766721"><span class="h2">Membrane damage</span><span class="headingEndMark"> — </span>Normal RBC precursors undergo orderly cytoskeletal and membrane assembly that includes spectrin, band 4.1, band 3 (the anion exchanger), and several other proteins, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef79183" href="/d/graphic/79183.html" rel="external">figure 4</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics"</a>.)</p><p>In vitro studies have demonstrated that in severe beta thalassemia, partially oxidized alpha globin chains are bound to the RBC membrane skeleton [<a href="#rid33">33</a>]. Likewise, in alpha thalassemia, partially oxidized beta globin has been demonstrated to be bound to membrane skeletons  (<a class="graphic graphic_figure graphicRef63845" href="/d/graphic/63845.html" rel="external">figure 5</a>) [<a href="#rid33">33,43</a>]. </p><p>Oxidative damage to membrane components, either indirectly through binding of globin chains or through direct oxidation of membrane proteins or lipids (see <a class="local">'Oxidative injury'</a> above), can affect various membrane properties:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymmetry of the bilayer</strong> – Asymmetry between the inner and outer leaflets of the lipid bilayer is a normal property of RBC membranes. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics", section on 'Lipid bilayer'</a>.)</p><p></p><p class="bulletIndent1">In thalassemias, normal membrane asymmetry is disrupted, and incorporation of membrane cytoskeletal proteins is frequently disorderly and discontinuous, especially in areas with alpha chain aggregates (in beta thalassemia) or Hb H inclusions (in alpha thalassemia) adjacent to the membrane, and at earlier stages of erythroid development [<a href="#rid44">44</a>]. Several abnormalities are seen, including increased levels of Band 3 (also called anion exchanger 1 [AE1]), which is the major integral membrane protein that stabilizes the RBC membrane and exchanges chloride ions for bicarbonate, along with decreased levels of band 4.1, which stabilizes spectrin-actin interactions [<a href="#rid45">45,46</a>]. Levels of spectrin and its binding partners (eg, ankyrin, actin) may be reduced [<a href="#rid46">46-49</a>]. Membrane preparations from individuals with Hb H disease reveal a large concentration of membrane-bound globin not present in control RBCs  (<a class="graphic graphic_figure graphicRef53915" href="/d/graphic/53915.html" rel="external">figure 6</a>) [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytoskeletal composition</strong> – Preparations of integral protein-rich fractions of RBC membranes, referred to as inside-out vesicles (IOVs), have demonstrated that Hb H RBC membranes contain only one-half the amount of spectrin as IOVs from normal RBCs [<a href="#rid46">46</a>]. Free spectrin, actin, and band 4.1 appear in the supernatant wash medium during the preparation of RBC membranes by stepwise hypotonic lysis of alpha thalassemic but not control RBCs [<a href="#rid47">47,50</a>]. The defect in membrane protein composition can be reproduced by adding heme-containing alpha globin chains to normal RBC membranes [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rigidity</strong> – Membranes from Hb H RBCs are two to three times more rigid than normal [<a href="#rid50">50,52</a>]. Membranes from patients with Hb H and Hb Constant Spring (Hb H/CS) are even more rigid [<a href="#rid53">53</a>], and the most rigid membranes are seen in Hb CS/CS [<a href="#rid52">52,53</a>]. Ektacytometric studies suggested that an interaction of the excess beta globin chains in Hb H RBCs with the cytosolic face of the membrane played an important role in the membrane rigidity [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">Rigidity may retard passage of Hb H RBCs through splenic and hepatic sinusoids. Extreme rigidity could lead to RBC fragmentation in parts of the vasculature in which there is elevated shear stress. This is consistent with RBC fragmentation observed on the peripheral blood smear. (See <a class="local">'CBC and RBC morphology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stability</strong> – Membrane stability is a technical term used to describe the ability of isolated RBC membranes to resist fragmentation under an intense elliptically deforming shear stress [<a href="#rid50">50</a>]. Membrane stability is generally thought to be a function of the RBC membrane skeleton and the interaction of the skeleton with the major transmembrane proteins, band 3 and glycophorin. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Membrane rigidity is increased in Hb H, further increased in Hb H/CS, and maximally increased in Hb CS/CS [<a href="#rid52">52</a>]. These changes are thought to be due to the membrane-bound beta globin and alpha CS globin chains. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, RBC membranes in beta thalassemia are highly friable and unstable, a change induced by partially oxidized alpha globin chains. (See <a class="local">'Oxidative injury'</a> above.)</p><p></p><p>These changes in membrane properties are thought to play an important role in the abnormal maturation and decreased deformability of thalassemic RBCs. In erythroid precursors, they may lead to increased apoptosis in the bone marrow. In mature RBCs, they may cause increased membrane expression of phosphatidylserine (PS) and neoantigens, all in turn leading to increased hemolysis, especially in the reticuloendothelial system. Hb H as well as Constant Spring variants (Hb H/CS and Hb CS/CS) RBCs have PS on the outer leaflet of the membrane [<a href="#rid54">54</a>]; the absolute number of such RBCs in the circulation is relatively small, although this may reflect their rapid removal from the circulation by the reticuloendothelial macrophages. (See <a class="local">'Ineffective erythropoiesis'</a> below and <a class="local">'Hemolysis'</a> below.)</p><p>In both alpha and beta thalassemia, membrane damage produced by the accumulation of excess globin chains (ie, excess alpha globin chains in beta thalassemia and excess beta globin chains in alpha thalassemia) may be reduced by the action of proteases that directly attack and partially destroy these excess globin chains but are incapable of eliminating the toxic chains [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1257721046"><span class="h2">Abnormal hydration</span><span class="headingEndMark"> — </span>RBC hydration refers to the ratio of water to hemoglobin and other solutes. Beta thalassemia RBCs are dehydrated, and alpha thalassemia RBCs are hyperhydrated  (<a class="graphic graphic_table graphicRef130100" href="/d/graphic/130100.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>In beta thalassemia, RBCs are dehydrated (they have a lower-than-normal ratio of water to solutes)  (<a class="graphic graphic_figure graphicRef60097" href="/d/graphic/60097.html" rel="external">figure 7</a>). The dehydrated cells have a high mean cell hemoglobin concentration (MCHC) and appear as dense on the peripheral blood smear  (<a class="graphic graphic_picture graphicRef76666" href="/d/graphic/76666.html" rel="external">picture 1</a>) [<a href="#rid50">50,56,57</a>]. This is thought to be due to excessive activation of the potassium-chloride cotransport system, a pH- and volume-activated ion channel that controls loss of <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a>  (<a class="graphic graphic_figure graphicRef62852" href="/d/graphic/62852.html" rel="external">figure 8</a>), with excess channel activity and ion export (remaining open in beta thalassemic RBCs more so than in normal RBCs) leading to water loss by osmotic mechanism [<a href="#rid50">50,58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In severe alpha thalassemia, RBCs are hyperhydrated (they have a higher-than-normal ratio of water to solutes). The proportion of hyperhydrated RBCs varies depending on the specific genotype [<a href="#rid53">53,59</a>]. It is an unproven hypothesis that in alpha thalassemia the potassium-chloride cotransporter closes down early, preventing the usual loss of <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> and water that is part of normal RBC physiology. Hb CS variants are hyperhydrated relative to Hb H RBCs [<a href="#rid59">59,60</a>].</p><p></p><p class="headingAnchor" id="H1775354791"><span class="h2">Reduced deformability</span><span class="headingEndMark"> — </span>Deformability (flexibility) is an essential property that enables RBCs with a diameter of 7 to 8 microns to traverse the capillary circulation, with a lumen diameter of approximately 3 microns, and the reticuloendothelial system, made up of macrophages lining slit-like sinusoids in the spleen (and liver) that are tortuous and narrower still. Reduced deformability delays passage through the microvascular bed and delays transit through the reticuloendothelial system, making them more susceptible to macrophage clearance. This contributes to extravascular hemolysis. (See <a class="local">'Hemolysis'</a> below.)</p><p>Deformability depends on the RBC having a specific surface area-to-volume ratio, relatively low cytoplasmic viscosity, and viscoelastic membrane properties. Poorly deformable RBCs are trapped and destroyed by reticuloendothelial macrophages in the spleen and liver. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics"</a>.)</p><p>Factors that reduce deformability in beta thalassemia include RBC dehydration and increased membrane rigidity [<a href="#rid50">50,61</a>]. In alpha thalassemia, Hb H cells would be expected to have increased deformability, and the mechanisms of reduced deformability are less well understood [<a href="#rid12">12,50</a>].</p><p class="headingAnchor" id="H368180160"><span class="h1">MECHANISMS OF ANEMIA</span></p><p class="headingAnchor" id="H555276838"><span class="h2">Overview of anemia mechanisms</span><span class="headingEndMark"> — </span>There are several mechanisms of anemia in the thalassemias. All of them appear to share a common underlying cause – an imbalance in the ratio of alpha (or alpha-like) and beta (or beta-like) globin chains during erythropoiesis.</p><p>In both alpha and beta thalassemias, there is a component of destruction of developing red blood cell (RBC) precursors in the bone marrow (ineffective erythropoiesis) as well as mature RBCs in the circulation (hemolysis). There is an increase in erythropoiesis, but it is insufficient to compensate for the decreased production and increased destruction of RBC precursors and mature RBCs. Since the rate of hemolysis in Hb H is only increased threefold, it is not clear why the marrow, which normally has a fivefold or greater capacity to increase erythropoiesis, does not do so [<a href="#rid62">62-64</a>]. Some elements of ineffective erythropoiesis may play a role.</p><p>For reasons that are only partially understood, the relative contributions of ineffective erythropoiesis in the bone marrow and hemolysis in the circulation differ in alpha versus beta thalassemia. In severe beta thalassemia, profound ineffective erythropoiesis in the bone marrow tends to predominate, with a component of peripheral blood hemolysis; in alpha thalassemia, the converse tends to occur, with a predominance of peripheral blood hemolysis and a lesser component of ineffective erythropoiesis in the bone marrow. </p><p class="headingAnchor" id="H15356659"><span class="h2">Ineffective erythropoiesis</span></p><p class="headingAnchor" id="H3295090291"><span class="h3">Overview of the process</span><span class="headingEndMark"> — </span>Ineffective erythropoiesis refers to reduced production of RBCs in the bone marrow due to destruction of mid- to late-stage maturing erythroblasts. It is characterized by a combination of apoptotic cell death and hemolysis of developing RBC precursors. The mechanism is incompletely understood. The pathophysiologic result is a major reduction in the output of reticulocytes into the circulation despite expansion of the developing pool of early erythroid precursors, due to premature destruction of these precursors within the bone marrow. </p><p>Ineffective erythropoiesis occurs in both alpha and beta thalassemia  (<a class="graphic graphic_table graphicRef130100" href="/d/graphic/130100.html" rel="external">table 2</a>); it is especially important in the pathophysiology of beta thalassemia. Toxic unpaired alpha chains have been demonstrated as early as the proerythroblast stage [<a href="#rid65">65-67</a>]. Free alpha chains were also shown to form dense cytoplasmic aggregates in basophilic, polychromatophilic, and orthochromatophilic erythroblasts (the final stages of RBC precursor development) [<a href="#rid43">43,44,65,66,68,69</a>]. (See  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p>The magnitude of ineffective erythropoiesis was initially underappreciated, until studies using radiolabeled iron were performed that demonstrated that in transfusion-dependent beta thalassemia, intramedullary cell death affected as much as 60 to 75 percent of developing RBC precursors [<a href="#rid70">70</a>]. Subsequently, the extent of apoptosis and erythroid expansion (numbers of developing erythroblasts) were shown to be increased in parallel [<a href="#rid71">71</a>].</p><p>Characteristic stages of ineffective erythropoiesis in beta thalassemia include expansion of the erythroid progenitor cell population and accelerated differentiation followed by maturation arrest and apoptosis at the polychromatophilic erythroblast stage (two steps before the reticulocyte) [<a href="#rid72">72</a>]. </p><p>Although the beta globin inclusions in hemoglobin H (Hb H) disease occur primarily in circulating RBCs as they age, excess beta globin chains also may accumulate and precipitate in erythroid precursors and may contribute to oxidant or other cellular injury that contributes to ineffective erythropoiesis in alpha thalassemia [<a href="#rid5">5,73,74</a>]. The mechanisms are likely similar but to a lesser extent than seen in beta thalassemia.</p><p class="headingAnchor" id="H3561266661"><span class="h3">Causes of ineffective erythropoiesis</span><span class="headingEndMark"> — </span>Mechanisms of ineffective erythropoiesis include apoptosis and phagocytosis by bone marrow macrophages.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apoptosis</strong> – A major cause of premature death of erythroid precursors is accelerated apoptosis [<a href="#rid69">69,71,75,76</a>]. One mechanism of apoptosis was shown to involve sequestration of heat shock proteins such as HSP70 by free alpha globin chains in the cytoplasm of the RBC precursors, causing maturation arrest and ultimately cell death [<a href="#rid77">77</a>]. Other proteins that regulate apoptosis such as caspases and cytochromes have been shown to be abnormally phosphorylated in bone marrow erythroblasts of some patients [<a href="#rid78">78</a>]. The extent of erythroid apoptosis correlates very closely with the extent of ineffective erythropoiesis in both alpha and beta thalassemia variants  (<a class="graphic graphic_figure graphicRef65431" href="/d/graphic/65431.html" rel="external">figure 9</a>) [<a href="#rid64">64</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phagocytosis</strong> – A second cause of premature cell death involves phagocytosis of developing erythroid precursors by bone marrow macrophages [<a href="#rid79">79</a>]. One of the consequences and hallmarks of apoptosis is the movement of phosphatidylserine (PS) from the inner to the outer leaflet of the membrane phospholipid bilayer. As mentioned above, the movement of PS to the outer leaflet may be one of the signals that promotes removal of thalassemic cells by the reticuloendothelial system. The deposition of IgG on the cell surface may promote phagocytosis in severe alpha thalassemia, as erythroblasts from patients with Hb H disease have excessive amounts of IgG on their surfaces [<a href="#rid80">80</a>]. Mechanisms of phagocytosis in the peripheral blood are discussed below. (See <a class="local">'Hemolysis'</a> below.) </p><p></p><p class="headingAnchor" id="H2911944355"><span class="h3">Consequences of ineffective erythropoiesis</span><span class="headingEndMark"> — </span>Downstream effects of ineffective erythropoiesis include erythroid expansion with extramedullary hematopoiesis and increased iron absorption:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythroid expansion</strong> – In severe forms of beta thalassemia, ineffective erythropoiesis is associated with extramedullary hematopoiesis (production of RBCs in other tissues besides the bone marrow, such as the liver and spleen).</p><p></p><p class="bulletIndent1">Erythroid expansion is driven by increased erythropoietin levels, although this may be blunted somewhat by inflammatory cytokines. GDF11, a cytokine in the transforming growth factor (TGF)-beta family, promotes the expansion of erythroid progenitor cells. Blockade of GDF11 in an animal model of thalassemia has been shown to correct several features of ineffective erythropoiesis including anemia, hemolysis, and iron overload. Potential therapies that could reduce GDF11 are under development for individuals with thalassemia. These therapies may work in part by reducing apoptosis of erythroid precursors [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis", section on 'TGF-beta gene family'</a>.)</p><p></p><p class="bulletIndent1">Erythroid expansion manifests as expansion of the bone marrow cavities that lead to bony distortion of the long bones, head, and facial bones, which are not normally used for erythropoiesis. Erythroid expansion in the spine can cause significant pain and neurologic deficits. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Skeletal changes'</a>.)</p><p></p><p class="bulletIndent1">In individuals with severely impaired erythropoiesis, RBC production may occur in extramedullary sites such as the spine, liver, and spleen. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Hepatosplenomegaly'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – Ineffective erythropoiesis also increases iron absorption and leads to increased total body iron. (See  <a class="medical medical_review" href="/d/html/7105.html" rel="external">"Regulation of iron balance", section on 'Systemic iron homeostasis'</a>.)</p><p></p><p class="headingAnchor" id="H3357831866"><span class="h2">Hemolysis</span><span class="headingEndMark"> — </span>Both alpha and beta thalassemias are characterized by hemolysis in the peripheral blood that shortens their survival to as much as one-third of that of normal RBCs (eg, down to 28 to 37 days to as short as 12 to 19 days) and contributes to anemia [<a href="#rid5">5,11,12,62,81,82</a>]. (See  <a class="medical medical_review" href="/d/html/7082.html" rel="external">"Red blood cell survival: Normal values and measurement"</a>.)</p><p>The mechanism is thought to involve membrane damage caused by aggregated, precipitated, and/or oxidized globin chains, as well as resulting changes in the mechanical properties of the RBCs (rigidity, dehydration, reduced deformability) that retard their passage through the sinusoids of the reticuloendothelial system and promote increased phagocytosis by reticuloendothelial macrophages [<a href="#rid24">24,33-35,45,48,81,83</a>]. Slower passage through the microvasculature allows macrophages of the reticuloendothelial organs to carefully scrutinize these RBCs and detect any cell surface signals that could alert the macrophages to retard, bind, and engulf the defective RBC.</p><p>Signals for phagocytosis have been studied extensively and may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced sialic acid in the membrane [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exteriorization of phosphatidylserine (PS), which in normal RBCs is confined to the inner membrane leaflet and sequestered from macrophages [<a href="#rid85">85</a>]. As noted above (see <a class="local">'Membrane damage'</a> above), in some beta thalassemic RBCs, the membrane bilayer is disrupted (presumably by oxidative damage) and PS is exposed on the outer membrane [<a href="#rid54">54,86</a>]. (See  <a class="medical medical_review" href="/d/html/7091.html" rel="external">"Red blood cell membrane: Structure and dynamics", section on 'Structural organization and dynamic regulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-RBC autoantibodies may form as the abnormal membrane proteins are exposed [<a href="#rid87">87</a>]. Oxidative damage from membrane-associated heme, hemichromes, and/or iron may cause membrane proteins to aggregate abnormally and create neoantigens [<a href="#rid88">88,89</a>]. As noted above, increases in membrane IgG and complement components are a likely contributor to the increased phagocytosis of alpha thalassemic RBCs [<a href="#rid90">90</a>]. Macrophages are able to identify the Fc domains of IgG on the RBC's outer membrane surface.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased cytokine production, especially tumor necrosis factor, may activate monocytes and macrophages and make them more phagocytic [<a href="#rid91">91</a>]. Serum concentrations of macrophage/monocyte colony-stimulating factor (M-CSF) are elevated in Hb H disease and correlate inversely with the patient's hemoglobin concentration [<a href="#rid92">92</a>]. </p><p></p><p>The importance of reticuloendothelial clearance of these abnormal cells is illustrated by the observation that individuals with beta thalassemia who have undergone splenectomy (and thus lack this clearance mechanism) have a greater proportion of RBCs with unstable and abnormal membranes [<a href="#rid50">50</a>]. Individuals with alpha thalassemia who have undergone splenectomy have increases in membrane RBC surface IgG levels.</p><p>In compound heterozygotes of Hb H disease and Hb Constant Spring (Hb H/CS), peripheral RBC destruction is increased, with a half-time of only 8.3 days (compared with a normal half-time of 26 days using the same assay) [<a href="#rid64">64</a>]. In homozygotes (Hb CS/CS), which should have the phenotype of an alpha thalassemia trait, the half-time is 13.7 days. Hb H/CS RBCs have more membrane associated IgG than either normal or Hb H RBCs [<a href="#rid80">80</a>]. </p><p class="headingAnchor" id="H3970762240"><span class="h1">CBC AND RBC MORPHOLOGY</span><span class="headingEndMark"> — </span>The effects of thalassemia on red blood cell (RBC) structure (see <a class="local">'Effects on the RBC'</a> above) lead to characteristic abnormalities on the complete blood count (CBC) and morphologic changes on the blood smear. These are summarized briefly below and discussed separately. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Laboratory testing'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia, RBC count, and reticulocyte count</strong> – Anemia (low hemoglobin and hematocrit) is a feature of most forms of thalassemia; mechanisms are multifactorial, as discussed above. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Anemia'</a> and <a class="local">'Mechanisms of anemia'</a> above.)</p><p></p><p class="bulletIndent1">Despite the overall reduction in hemoglobin and hematocrit, the number of RBCs (RBC count) is typically normal-to-increased in thalassemias, as the bone marrow produces increased numbers of small cells. This combination of decreased hemoglobin and hematocrit with increased or normal RBC count is one of the features that leads clinicians to suspect thalassemia rather than iron deficiency when evaluating microcytic anemia. In iron deficiency, there are parallel decreases in hemoglobin, hematocrit, and RBC count. (See  <a class="medical medical_review" href="/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia", section on 'Overview'</a>.)</p><p></p><p class="bulletIndent1">The reticulocyte count may be increased due to increased erythropoiesis [<a href="#rid12">12,13,63</a>]. However, the count is often inappropriately low for the degree of anemia, reflecting the effects of ineffective erythropoiesis, which impedes the output of red cells relative to what one would expect for the degree of erythropoietin stimulation of early progenitors.</p><p></p><p class="bulletIndent1">Other indicators of increased erythrocyte activity include increased erythropoietin levels and soluble transferrin receptor (sTfR) [<a href="#rid93">93,94</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC indices and</strong> <strong>morphology</strong> – Unbalanced globin chain synthesis leads to a global reduction in hemoglobin per cell (low mean corpuscular hemoglobin).</p><p></p><p class="bulletIndent1">RBCs in alpha thalassemia are small and under-hemoglobinized, leading to microcytosis and hypochromia (low mean corpuscular volume [MCV] and low mean corpuscular hemoglobin [MCH]). The hypochromia is due to a combination of reduced hemoglobin per cell as well as hyperhydration. The microcytosis occurs due to a reduction in cell volume caused by reduced hemoglobin content.</p><p></p><p class="bulletIndent1">RBC morphology can be quite abnormal in severe thalassemias, with fragmentation and bizarre shapes. Target cells, teardrop cells, burr cells (echinocytes), and fragmented forms (schistocytes) can be seen. The blood smear images illustrate typical findings in beta thalassemia  (<a class="graphic graphic_picture graphicRef76666" href="/d/graphic/76666.html" rel="external">picture 1</a>) and alpha thalassemia  (<a class="graphic graphic_picture graphicRef80776" href="/d/graphic/80776.html" rel="external">picture 2</a>). The severity of the abnormalities depends on disease severity. Nucleated RBCs are also common, especially following splenectomy. Individuals receiving regular transfusions may have populations of normal-appearing RBCs interspersed with thalassemic cells.</p><p></p><p class="bulletIndent1">Fragmented RBCs are likely to have reduced deformability and greater difficulty undergoing the elliptical deformation that allows them to traverse reticuloendothelial sinusoids; thus, fragmentation is likely to contribute to further hemolysis. (See <a class="local">'Effects on the RBC'</a> above and <a class="local">'Hemolysis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RBC inclusions</strong> – Unpaired globin chains can precipitate and produce intracellular inclusions in developing and mature circulating RBCs. In beta thalassemia, precipitated alpha chains can form large inclusions [<a href="#rid21">21</a>]. In alpha thalassemias, these are composed of beta globin tetramers (hemoglobin H [Hb H]). These inclusions increase in individuals who have undergone splenectomy [<a href="#rid5">5</a>]. They can also be induced by incubating RBCs with mild oxidants such as brilliant cresyl blue or new <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>  (<a class="graphic graphic_picture graphicRef77536" href="/d/graphic/77536.html" rel="external">picture 3</a>) [<a href="#rid5">5,12,13,53</a>]. </p><p></p><p class="bulletIndent1">When RBCs from patients with Hb H disease are separated by density into young, middle aged, and old cells, the level of soluble Hb H is highest in young cells, where the number of inclusion-containing cells is lowest. As the cells age and become denser, soluble Hb H decreases and inclusions increase [<a href="#rid5">5</a>]. The abundance of inclusions correlates with the cytosolic concentration of Hb H [<a href="#rid95">95</a>]. Electron microscopy studies have characterized the inclusions and documented that they are composed of beta globin chains [<a href="#rid43">43,53</a>].</p><p></p><p class="headingAnchor" id="H488292859"><span class="h1">IRON OVERLOAD</span></p><p class="headingAnchor" id="H152344838"><span class="h2">Causes of iron overload</span><span class="headingEndMark"> — </span>Iron overload can occur in beta and alpha thalassemia. There are two main mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusions</strong> – Significant total body iron overload can occur after as few as 15 to 20 transfusions. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ineffective erythropoiesis</strong> – Ineffective erythropoiesis, with death of developing red blood cell precursors in the bone marrow, causes a significant increase in intestinal iron absorption by an incompletely understood mechanism. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Ineffective erythropoiesis'</a>.)</p><p></p><p class="bulletIndent1">Although the mechanism is incompletely understood, it is thought to involve reduced levels of hepcidin. (See  <a class="medical medical_review" href="/d/html/7105.html" rel="external">"Regulation of iron balance", section on 'Intestinal iron absorption'</a> and  <a class="medical medical_review" href="/d/html/7105.html" rel="external">"Regulation of iron balance", section on 'Hepcidin'</a>.)</p><p></p><p class="bulletIndent1">Both anemia and increased erythropoiesis lead to suppression of hepcidin and, therefore, increased iron absorption. An important proximal regulator is erythroferrone, a member of the C1q-tumor necrosis factor (TNF) family of proteins that is produced by maturing erythroblasts in response to erythropoietin [<a href="#rid96">96,97</a>]. Studies in an animal model suggest that increased erythroferrone may be the principal contributor to excessive iron absorption in thalassemia [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1">Reduced levels of hepcidin lead to increased iron uptake from the intestine and bone marrow macrophages. (See  <a class="medical medical_review" href="/d/html/7105.html" rel="external">"Regulation of iron balance", section on 'Hepcidin'</a>.)</p><p></p><p>Thus, in individuals with thalassemia, iron overload can occur even in the absence of transfusions but is greatly exacerbated by transfusions.</p><p>Increased iron absorption leads to increases in the levels of storage iron as well as free iron, also called non-transferrin-bound iron (NTBI). Increased storage iron is reflected as increased serum transferrin saturation (TSAT), increased serum ferritin, and increased macrophage iron in the bone marrow [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Sequence and interpretation of testing'</a>.)</p><p class="headingAnchor" id="H3708506378"><span class="h2">Consequences of iron overload</span><span class="headingEndMark"> — </span>The consequences of excess total body iron are many-fold, and thought to be principally due to the effects of reactive oxygen species that can affect the following organ systems:</p><p class="bulletIndent1"><span class="glyph">●</span>Heart</p><p class="bulletIndent1"><span class="glyph">●</span>Liver</p><p class="bulletIndent1"><span class="glyph">●</span>Kidneys</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid</p><p class="bulletIndent1"><span class="glyph">●</span>Gonads</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreas</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow</p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary gland</p><p class="bulletIndent1"><span class="glyph">●</span>Parathyroid glands</p><p></p><p>In a series of 174 patients with transfusion-dependent thalassemia who were receiving regular transfusions and chelation therapy, NTBI was detected in 83 percent; all patients with heart disease had increased NTBI; and all patients without NTBI were free of heart disease [<a href="#rid99">99</a>]. (See <a class="local">'Organ damage'</a> below and  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload", section on 'Consequences of excess iron stores'</a>.) </p><p>The evaluation and management of excess iron stores in patients with thalassemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Rule out iron deficiency'</a> and  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p class="headingAnchor" id="H3775718393"><span class="h1">OTHER DISEASE COMPLICATIONS</span></p><p class="headingAnchor" id="H4289520847"><span class="h2">Hypercoagulable state</span><span class="headingEndMark"> — </span>Several reports have described an increased risk of thromboembolic complications in thalassemia [<a href="#rid100">100-102</a>]. In a retrospective series of 584 individuals with beta thalassemia intermedia, thrombosis was observed in 82 (14 percent) [<a href="#rid103">103</a>]. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a>.)</p><p>The mechanisms are incompletely understood. It has been suggested that increased phosphatidylserine (PS) on the outer leaflet of the red blood cell (RBC) membrane may promote thrombosis, similar to the role of PS in promoting coagulation on the surface of activated platelets [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Multicomponent complexes'</a>.)</p><p>Other hemostatic changes may include alterations in the levels of procoagulant or anticoagulant factors and/or chronic activation of platelets, endothelial cells, or white blood cells [<a href="#rid100">100</a>]. Splenectomy may also increase the risk of thrombosis [<a href="#rid105">105,106</a>]. Similarity to the increased risk of thromboembolism in sickle cell disease has also been suggested. However, as high-quality evidence for the increased risk of thrombophilia is lacking, we manage patients with thalassemia in a manner similar to the general population. Further study of this issue is warranted.</p><p class="headingAnchor" id="H1097291916"><span class="h2">Organ damage</span><span class="headingEndMark"> — </span>Organ damage in beta thalassemia is due to the combined effects of anemia, chronic hypoxia, iron overload, and possibly other disease features such as a chronic inflammatory state. These complications tend to be more pronounced in beta thalassemia than in alpha thalassemia. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney disease</strong> – Kidney disease may result from extramedullary hematopoiesis involving the kidney, hyperuricemia, and other metabolic effects of increased hematopoietic cell turnover [<a href="#rid107">107</a>]. Iron overload may also be toxic to the kidney. Some iron chelating agents such as <a class="drug drug_general" data-topicid="8794" href="/d/drug information/8794.html" rel="external">deferasirox</a> may also be nephrotoxic. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Hypercalciuria and kidney stones are common in thalassemia second to endocrine disease, bone disease, and iron chelators [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart disease</strong> – Heart disease including cardiomyopathy and pulmonary hypertension are multifactorial. Iron toxicity plays a major role in cardiac dysfunction. Other factors may include hemolysis, chronic anemia, endocrinopathy, vascular changes, and pulmonary disease. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Heart failure and arrhythmias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes</strong> – Diabetes and other endocrine and metabolic abnormalities may result from iron deposition and oxidative damage to pancreatic cells. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Endocrine and metabolic abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone disease</strong> – Decreased bone density is common and increases the risk of fracture and skeletal deformities. Contributing factors may include endocrine disorders, iron toxicity, and erythroid proliferation. Additional data suggest that erythroferrone may contribute by modifying the availability of bone morphogenetic protein (BMP) for osteoclast activity [<a href="#rid109">109</a>]. Increased osteoclast activity may be induced by cytokines of the tumor necrosis factor (TNF) family. </p><p></p><p class="headingAnchor" id="H4024029234"><span class="h2">Susceptibility to Yersinia infection</span><span class="headingEndMark"> — </span>Infection with <em>Yersinia enterocolitica</em> is a significant cause of morbidity in patients with thalassemia (as well as other iron overload syndromes such as chronic liver disease and hereditary hemochromatosis) [<a href="#rid110">110,111</a>]. (See  <a class="medical medical_review" href="/d/html/3139.html" rel="external">"Yersiniosis: Infection due to Yersinia enterocolitica and Yersinia pseudotuberculosis"</a>.)</p><p><em>Yersinia enterocolitica</em> is a siderophilic (iron-loving) organism; it contains several pathways to facilitate iron-uptake, which is essential for its growth [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/d/html/3139.html" rel="external">"Yersiniosis: Infection due to Yersinia enterocolitica and Yersinia pseudotuberculosis"</a>.)</p><p>Iron chelation with desferrioxamine may make circulating iron more bioavailable to <em>Yersinia</em>. RBC transfusions may also provide a rich source of iron. In a series of 14 individuals with thalassemia who developed a <em>Yersinia</em> infection, 57 percent of the infections occurred within 10 days of blood transfusion [<a href="#rid111">111</a>]. Recognition of these associations and unusual manifestations in these patients, such as an appendicitis-like syndrome, may direct clinicians to earlier anti-yersinial therapy, along with temporary cessation of chelation [<a href="#rid110">110,113</a>]. (See  <a class="medical medical_review" href="/d/html/3139.html" rel="external">"Yersiniosis: Infection due to Yersinia enterocolitica and Yersinia pseudotuberculosis"</a>.)</p><p class="headingAnchor" id="H1550496875"><span class="h1">REDUCED MALARIA RISK</span><span class="headingEndMark"> — </span>The high prevalence of thalassemia, especially in regions of the world where malaria is (or was) endemic, suggests evolutionary pressure to retain disease variants; this appears to have been driven by a reduction in malarial risk, since thalassemic red blood cells (RBCs) offer innate protection against severe malaria due to <em>Plasmodium falciparum</em> [<a href="#rid114">114-119</a>]. </p><p>This effect is more pronounced in alpha thalassemia, but beta thalassemia does offer some protection. Malaria resistance appears to be due to reduced parasite multiplication within RBCs rather than reduced parasite invasion [<a href="#rid120">120</a>]. </p><p>The mechanisms are incompletely understood and may include oxidant injury, persistence of fetal hemoglobin, and enhanced macrophage clearance [<a href="#rid114">114,115,117,120-122</a>]. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7099.html" rel="external">"Protection against malaria by variants in red blood cell (RBC) genes"</a>.)</p><p class="headingAnchor" id="H2183462294"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H14576584"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and definitions</strong> – Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). Beta thalassemia is due to impaired production of beta globin chains; alpha thalassemia is due to impaired production of alpha globin chains. Terminology has shifted to the use of transfusion dependent or non-transfusion-dependent as more clinically meaningful. (See <a class="local">'Terminology and disease classification'</a> above.)</p><p></p><p class="bulletIndent1">The severity of beta thalassemia may also be affected by other genetic variation that affects the ratio of alpha globin to beta globin, including concomitant alpha thalassemia, hereditary persistence of fetal hemoglobin, concomitant sickle hemoglobin mutation, or concomitant hemoglobin E. (See <a class="local">'Combinations of hemoglobin variants'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Globin chain imbalance</strong> – Reduced production of one type of globin chain (alpha or beta) disrupts the normally tightly controlled ratio of 1.00±0.05. Beta thalassemia mutations affect beta chains but not embryonic (epsilon) or fetal (gamma) chains; thus, the age of onset of beta thalassemia is in early childhood rather than during fetal development  (<a class="graphic graphic_figure graphicRef109086" href="/d/graphic/109086.html" rel="external">figure 3</a>). Alpha chains are used during fetal development; thus, alpha thalassemia manifests before birth. In the fetus and during early infancy, excess gamma globin chains form tetramers, creating Hb Barts. In childhood and adulthood, excess beta globin chains form tetramers, creating Hb H. Differences in the pathophysiology of alpha and beta thalassemia are summarized in the table  (<a class="graphic graphic_table graphicRef130100" href="/d/graphic/130100.html" rel="external">table 2</a>). (See <a class="local">'Globin chain imbalance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxidative injury</strong> – Unpaired alpha or beta chains with an attached heme moiety are susceptible to oxidation to form hemichromes, which can generate reactive oxygen species (ROS). These can cause oxidant injury and damage red blood cell (RBC) membranes directly, via effects on cytoskeletal or integral membrane proteins or lipids, or indirectly by affecting the globin chains that bind to the membranes. (See <a class="local">'Oxidative injury'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered RBC</strong> <strong>properties</strong> – Oxidative damage to membrane components reduces the normal asymmetry between the inner and outer leaflets of the lipid bilayer and may cause increased membrane expression of phosphatidylserine (PS) and neoantigens. Membrane stability is increased in alpha thalassemia and decreased in beta thalassemia. These changes interfere with normal maturation of RBCs and the deformability needed to traverse sinusoids in the liver and spleen. In erythroid precursors, they may lead to increased apoptosis in the bone marrow. In mature RBCs, they may lead to increased hemolysis. (See <a class="local">'Membrane damage'</a> above and <a class="local">'Abnormal hydration'</a> above and <a class="local">'Reduced deformability'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of anemia</strong> – Alpha and beta thalassemias both have a component of ineffective erythropoiesis (destruction of developing RBC precursors in the bone marrow) and hemolysis (destruction of circulating mature RBCs). The relative contributions differ in the different thalassemias  (<a class="graphic graphic_table graphicRef130100" href="/d/graphic/130100.html" rel="external">table 2</a>). In beta thalassemia, ineffective erythropoiesis tends to predominate; in severe beta thalassemia this can be associated with extramedullary hematopoiesis (production of RBCs in other tissues besides the bone marrow, such as the liver and spleen). In alpha thalassemia, peripheral blood hemolysis plays a larger role. (See <a class="local">'Overview of anemia mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CBC and blood smear</strong> – The severity of abnormalities on the complete blood count (CBC) and blood smear depends on disease severity. The blood smear images illustrate typical findings in beta thalassemia  (<a class="graphic graphic_picture graphicRef76666" href="/d/graphic/76666.html" rel="external">picture 1</a>) and alpha thalassemia  (<a class="graphic graphic_picture graphicRef80776" href="/d/graphic/80776.html" rel="external">picture 2</a>). (See <a class="local">'CBC and RBC morphology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There may be anemia with a normal-to-increased RBC count. </p><p class="bulletIndent2"><span class="glyph">•</span>The reticulocyte count may be increased but is often inappropriately low given the degree of anemia. </p><p class="bulletIndent2"><span class="glyph">•</span>RBCs can be microcytic (low mean corpuscular volume [MCV]) and hypochromic (low mean corpuscular hemoglobin [MCH]). </p><p class="bulletIndent2"><span class="glyph">•</span>Morphology can be quite abnormal with fragmentation, bizarre shapes, target cells, teardrop cells, and burr cells (echinocytes).</p><p class="bulletIndent2"><span class="glyph">•</span>Nucleated RBCs are also common, especially following splenectomy. </p><p class="bulletIndent2"><span class="glyph">•</span>Precipitated globin chains can produce large intracellular inclusions. </p><p class="bulletIndent2"><span class="glyph">•</span>Individuals receiving regular transfusions may have populations of normal-appearing RBCs interspersed with thalassemic cells. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – There are two main mechanisms of iron overload in the thalassemias: transfusions and ineffective erythropoiesis. Iron overload can occur after as few as 15 to 20 transfusions. Ineffective erythropoiesis causes a significant increase in intestinal iron absorption by an incompletely understood mechanism thought to involve reduced levels of hepcidin. Iron overload can affect the heart, liver, kidneys, endocrine organs (thyroid, pancreas, gonads), and bone marrow. (See <a class="local">'Iron overload'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other complications</strong> – Other potential complications include a hypercoagulable state; organ damage caused by iron overload, anemia, chronic hypoxia, and possibly chronic inflammatory state; and increased risk of infection with the siderophilic (iron-loving) organism <em>Yersinia enterocolitica</em>. (See <a class="local">'Other disease complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical implications</strong> – (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)"</a> and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing"</a> and  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a> and  <a class="medical medical_review" href="/d/html/3554.html" rel="external">"Hematopoietic stem cell transplantation for transfusion-dependent thalassemia"</a>.)</p><p></p><p class="headingAnchor" id="H104401447"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges extensive contributions of Donald H Mahoney, Jr, MD, and William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ng PC, Fok TF, Lee CH, et al. Is homozygous alpha-thalassaemia a lethal condition in the 1990s? Acta Paediatr 1998; 87:1197.</a></li><li><a class="nounderline abstract_t">Hayward A, Ambruso D, Battaglia F, et al. Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. Fetal Diagn Ther 1998; 13:8.</a></li><li><a class="nounderline abstract_t">Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood 1998; 91:2213.</a></li><li><a class="nounderline abstract_t">Gabuzda TG. Hemoglobin H and the red cell. Blood 1966; 27:568.</a></li><li><a class="nounderline abstract_t">RIGAS DA, KOLER RD. Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy. Blood 1961; 18:1.</a></li><li><a class="nounderline abstract_t">BENESCH R, BENESCH RE. PROPERTIES OF HAEMOGLOBIN H AND THEIR SIGNIFICANCE IN RELATION TO FUNCTION OF HAEMOGLOBIN. Nature 1964; 202:773.</a></li><li><a class="nounderline abstract_t">Randhawa ZI, Jones RT, Lie-Injo LE. Human hemoglobin Portland II (zeta 2 beta 2). Isolation and characterization of Portland hemoglobin components and their constituent globin chains. J Biol Chem 1984; 259:7325.</a></li><li><a class="nounderline abstract_t">DANCE N, HUEHNS ER, BEAVEN GH. The abnormal haemoglobins in haemoglobin-H disease. Biochem J 1963; 87:240.</a></li><li><a class="nounderline abstract_t">Wood WG, Stamatoyannopoulos G. synthesis during erythroid cell maturation in alpha thalassemia. Hemoglobin 1976-77; 1:135.</a></li><li><a class="nounderline abstract_t">Lehmann H. Different types of alpha-thalassemia and significance of haemoglobin Bart's in neonates. Lancet 1970; 2:78.</a></li><li><a class="nounderline abstract_t">Nathan DG, Gunn RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med 1966; 41:815.</a></li><li><a class="nounderline abstract_t">RIGAS DA, KOLER RD, OSGOOD EE. Hemoglobin H; clinical, laboratory, and genetic studies of a family with a previously undescribed hemoglobin. J Lab Clin Med 1956; 47:51.</a></li><li><a class="nounderline abstract_t">Gouttas A, Fessas PH, Tsevrenis H, et al. Description d'une nouvelle variété d'anémie hémolytique congénitale. Vox Sang 1955; 26:911.</a></li><li><a class="nounderline abstract_t">Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 2000; 343:544.</a></li><li><a class="nounderline abstract_t">Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today 1995; 1:15.</a></li><li><a class="nounderline abstract_t">Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/beta-thalassaemia: a common &amp; clinically diverse disorder. Indian J Med Res 2011; 134:522.</a></li><li><a class="nounderline abstract_t">Kalpravidh RW, Komolvanich S, Wilairat P, Fucharoen S. Globin chain turnover in reticulocytes from patients with beta (0) -thalassaemia/Hb E disease. Eur J Haematol 1995; 55:322.</a></li><li><a class="nounderline abstract_t">Sripichai O, Makarasara W, Munkongdee T, et al. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 2008; 83:482.</a></li><li><a class="nounderline abstract_t">Jones E, Pasricha SR, Allen A, et al. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Blood 2015; 125:873.</a></li><li><a class="nounderline abstract_t">Efremov GD. Dominantly Inherited beta-Thalassemia. Hemoglobin 2007; 31:193.</a></li><li><a class="nounderline abstract_t">FESSAS P. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. Blood 1963; 21:21.</a></li><li><a class="nounderline abstract_t">FESSAS P, LOUKOPOULOS D. ALPHA-CHAIN OF HUMAN HEMOGLOBIN: OCCURRENCE IN VIVO. Science 1964; 143:590.</a></li><li><a class="nounderline abstract_t">Polliack A, Yataganas X, Rachmilewitz EA. Ultrastructure of the inclusion bodies and nuclear abnormalities in beta-thalassemic erythroblasts. Ann N Y Acad Sci 1974; 232:261.</a></li><li><a class="nounderline abstract_t">Traeger-Synodinos J, Kanavakis E, Vrettou C, et al. The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies. Br J Haematol 1996; 95:467.</a></li><li class="breakAll">Pryor WA. Free radicals in biology: The involvement of radical reactions in aging and carcinogens: Proceedings of the Vth International Congress on Medical Chemistry, Farnoux CC (Ed), Elsevier, Holland 1977. p.331.</li><li><a class="nounderline abstract_t">Rachmilewitz EA. Denaturation of the normal and abnormal hemoglobin molecule. Semin Hematol 1974; 11:441.</a></li><li><a class="nounderline abstract_t">Rachmilewitz EA, Peisach J, Bradley TB, Blumberg WE. Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease. Nature 1969; 222:248.</a></li><li><a class="nounderline abstract_t">Rachmilewitz EA, Peisach J, Blumberg WE. Studies on the stability of oxyhemoglobin A and its constituent chains and their derivatives. J Biol Chem 1971; 246:3356.</a></li><li><a class="nounderline abstract_t">Filosa A, Valgimigli L, Pedulli GF, et al. Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy. Br J Haematol 2005; 131:135.</a></li><li><a class="nounderline abstract_t">Waugh SM, Low PS. Hemichrome binding to band 3: nucleation of Heinz bodies on the erythrocyte membrane. Biochemistry 1985; 24:34.</a></li><li><a class="nounderline abstract_t">Hebbel RP. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14:129.</a></li><li><a class="nounderline abstract_t">Cappellini MD, Tavazzi D, Duca L, et al. Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassaemia intermedia. Br J Haematol 1999; 104:504.</a></li><li><a class="nounderline abstract_t">Advani R, Sorenson S, Shinar E, et al. Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia. Blood 1992; 79:1058.</a></li><li><a class="nounderline abstract_t">Scott MD, Rouyer-Fessard P, Lubin BH, Beuzard Y. Entrapment of purified alpha-hemoglobin chains in normal erythrocytes. A model for beta thalassemia. J Biol Chem 1990; 265:17953.</a></li><li><a class="nounderline abstract_t">Scott MD, Rouyer-Fessard P, Ba MS, et al. Alpha- and beta-haemoglobin chain induced changes in normal erythrocyte deformability: comparison to beta thalassaemia intermedia and Hb H disease. Br J Haematol 1992; 80:519.</a></li><li><a class="nounderline abstract_t">Scott MD, van den Berg JJ, Repka T, et al. Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest 1993; 91:1706.</a></li><li><a class="nounderline abstract_t">Browne PV, Shalev O, Kuypers FA, et al. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest 1997; 100:1459.</a></li><li><a class="nounderline abstract_t">Repka T, Shalev O, Reddy R, et al. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood 1993; 82:3204.</a></li><li><a class="nounderline abstract_t">Schrier SL, Mohandas N. Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties. Blood 1992; 79:1586.</a></li><li><a class="nounderline abstract_t">Cheng ML, Ho HY, Tseng HC, et al. Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br J Haematol 2005; 128:119.</a></li><li><a class="nounderline abstract_t">Nathan DG, Stossel TB, Gunn RB, et al. Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia. J Clin Invest 1969; 48:33.</a></li><li><a class="nounderline abstract_t">Prasartkaew S, Bunyaratvej A, Fucharoen S, Wasi P. Comparison of erythrocyte antioxidative enzyme activities between two types of haemoglobin H disease. J Clin Pathol 1986; 39:1299.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Lee MJ, Furukawa T, et al. Composition of the intra-erythroblastic precipitates in thalassaemia and congenital dyserythropoietic anaemia (CDA): identification of a new type of CDA with intra-erythroblastic precipitates not reacting with monoclonal antibodies to alpha- and beta-globin chains. Br J Haematol 1996; 93:576.</a></li><li><a class="nounderline abstract_t">Aljurf M, Ma L, Angelucci E, et al. Abnormal assembly of membrane proteins in erythroid progenitors of patients with beta-thalassemia major. Blood 1996; 87:2049.</a></li><li><a class="nounderline abstract_t">Shinar E, Shalev O, Rachmilewitz EA, Schrier SL. Erythrocyte membrane skeleton abnormalities in severe beta-thalassemia. Blood 1987; 70:158.</a></li><li><a class="nounderline abstract_t">Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest 1989; 83:404.</a></li><li><a class="nounderline abstract_t">Yuan J, Bunyaratvej A, Fucharoen S, et al. The instability of the membrane skeleton in thalassemic red blood cells. Blood 1995; 86:3945.</a></li><li><a class="nounderline abstract_t">Rouyer-Fessard P, Garel MC, Domenget C, et al. A study of membrane protein defects and alpha hemoglobin chains of red blood cells in human beta thalassemia. J Biol Chem 1989; 264:19092.</a></li><li><a class="nounderline abstract_t">Lamchiagdhase P, Wilairat P, Sahaphong S, et al. Defective spectrin dimer self-association in thalassemic red cells. Eur J Haematol 1987; 38:246.</a></li><li><a class="nounderline abstract_t">Schrier SL, Rachmilewitz E, Mohandas N. Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: implication for differences in clinical manifestations. Blood 1989; 74:2194.</a></li><li><a class="nounderline abstract_t">Shalev O, Shinar E, Lux SE. Isolated beta-globin chains reproduce, in normal red cell membranes, the defective binding of spectrin to alpha-thalassaemic membranes. Br J Haematol 1996; 94:273.</a></li><li><a class="nounderline abstract_t">Schrier SL, Bunyaratvej A, Khuhapinant A, et al. The unusual pathobiology of hemoglobin constant spring red blood cells. Blood 1997; 89:1762.</a></li><li><a class="nounderline abstract_t">Bunyaratvej A, Sahaphong S, Bhamarapravati N, Wasi P. Different patterns of intraerythrocytic inclusion body distribution in the two types of haemoglobin H disease. An ultrastructural study. Acta Haematol 1983; 69:314.</a></li><li><a class="nounderline abstract_t">Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998; 91:3044.</a></li><li><a class="nounderline abstract_t">Sancar GB, Cedeno MM, Rieder RF. Rapid destruction of newly synthesized excess beta-globin chains in HbH disease. Blood 1981; 57:967.</a></li><li><a class="nounderline abstract_t">Fortier N, Snyder LM, Garver F, et al. The relationship between in vivo generated hemoglobin skeletal protein complex and increased red cell membrane rigidity. Blood 1988; 71:1427.</a></li><li><a class="nounderline abstract_t">Rund D, Filon D, Strauss N, et al. Mean corpuscular volume of heterozygotes for beta-thalassemia correlates with the severity of mutations. Blood 1992; 79:238.</a></li><li><a class="nounderline abstract_t">Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.</a></li><li><a class="nounderline abstract_t">Bunyaratvej A, Butthep P, Fucharoen S, Saw D. Erythrocyte volume and haemoglobin concentration in haemoglobin H disease: discrimination between the two genotypes. Acta Haematol 1992; 87:1.</a></li><li><a class="nounderline abstract_t">Pootrakul P, Winichagoon P, Fucharoen S, et al. Homozygous haemoglobin Constant Spring: a need for revision of concept. Hum Genet 1981; 59:250.</a></li><li><a class="nounderline abstract_t">Dondorp AM, Chotivanich KT, Fucharoen S, et al. Red cell deformability, splenic function and anaemia in thalassaemia. Br J Haematol 1999; 105:505.</a></li><li><a class="nounderline abstract_t">PEARSON HA, McFARLAND W. Erythrokinetics in thalassemia. II. Studies in Lepore trait and hemoglobin H disease. J Lab Clin Med 1962; 59:147.</a></li><li><a class="nounderline abstract_t">Malamos B, Gyftaki E, Binopoulos D, et al. Studies of haemoglobin synthesis and red cell survival in haemoglobinopathy. Acta Haematol 1962; 28:124.</a></li><li><a class="nounderline abstract_t">Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood 2000; 96:2606.</a></li><li><a class="nounderline abstract_t">Polliack A, Rachmilewitz EA. Ultrastructural studies in -thalassaemia major. Br J Haematol 1973; 24:319.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Bush V. Observations on the ultrastructure of erythropoietic cells and reticulum cells in the bone marrow of patients with homozygous beta-thalassaemia. Br J Haematol 1975; 30:395.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Hughes M. Ultrastructural studies of erythropoiesis in beta-thalassaemia trait. Br J Haematol 1980; 46:401.</a></li><li><a class="nounderline abstract_t">Fessas P, Loukopoulos D, Kaltsoya A. Peptide analysis of the inclusions of erythroid cells in beta-thalassemia. Biochim Biophys Acta 1966; 124:430.</a></li><li><a class="nounderline abstract_t">Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993; 82:374.</a></li><li><a class="nounderline abstract_t">Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49:17.</a></li><li><a class="nounderline abstract_t">Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000; 96:3624.</a></li><li><a class="nounderline abstract_t">Arlet JB, Dussiot M, Moura IC, et al. Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies. Curr Opin Hematol 2016; 23:181.</a></li><li><a class="nounderline abstract_t">Fessas P, Yatachanas X. Intraerythroblastic instability of hemoglobin beta-4 (Hgb H). Blood 1968; 31:323.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Hughes M, Fucharoen S, Wasi P. The fate of excess beta-globin chains within erythropoietic cells in alpha-thalassaemia 2 trait, alpha-thalassaemia 1 trait, haemoglobin H disease and haemoglobin Q-H disease: an electron microscope study. Br J Haematol 1984; 56:473.</a></li><li><a class="nounderline abstract_t">Angelucci E, Lucarelli G, Yuan J, et al. rogrammed cell death (PCD) and ineffective erythropoiesis in Cooley's anemia. Blood 1996; 88:S2817.</a></li><li><a class="nounderline abstract_t">Angelucci E, Ma L, Lucarelli G, et al. The role of iron overload in the extent of programmed cell death (PCD) in patients with Cooley's anemia. Blood 1997; 90:S2839.</a></li><li><a class="nounderline abstract_t">Arlet JB, Ribeil JA, Guillem F, et al. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia. Nature 2014; 514:242.</a></li><li><a class="nounderline abstract_t">Ponnikorn S, Panichakul T, Sresanga K, et al. Phosphoproteomic analysis of apoptotic hematopoietic stem cells from hemoglobin E/β-thalassemia. J Transl Med 2011; 9:96.</a></li><li><a class="nounderline abstract_t">Angelucci E, Bai H, Centis F, et al. Enhanced macrophagic attack on beta-thalassemia major erythroid precursors. Haematologica 2002; 87:578.</a></li><li><a class="nounderline abstract_t">Wiener E, Wanachiwanawin W, Kotipan K, et al. Erythroblast- and erythrocyte-bound antibodies in alpha and beta thalassaemia syndromes. Transfus Med 1991; 1:229.</a></li><li><a class="nounderline abstract_t">Vigi V, Volpato S, Gaburro D, et al. The correlation between red-cell survival and excess of alpha-globin synthesis in beta-thalassemia. Br J Haematol 1969; 16:25.</a></li><li><a class="nounderline abstract_t">GABUZDA TG, NATHAN DG, GARDNER FH. THE METABOLISM OF THE INDIVIDUAL C14 LABELED HEMOGLOBINS IN PATIENTS WITH H-THALASSEMIA, WITH OBSERVATIONS ON RADIOCHROMATE BINDING TO THE HEMOGLOBINS DURING RED CELL SURVIVAL. J Clin Invest 1965; 44:315.</a></li><li><a class="nounderline abstract_t">Rachmilewitz EA, Shinar E, Shalev O, et al. Erythrocyte membrane alterations in beta-thalassaemia. Clin Haematol 1985; 14:163.</a></li><li><a class="nounderline abstract_t">Knyszynski A, Danon D, Kahane I, Rachmilewitz EA. Phagocytosis of nucleated and mature beta thalassaemic red blood cells by mouse macrophages in vitro. Br J Haematol 1979; 43:251.</a></li><li><a class="nounderline abstract_t">Allen TM, Williamson P, Schlegel RA. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc Natl Acad Sci U S A 1988; 85:8067.</a></li><li><a class="nounderline abstract_t">Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, et al. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993; 44:63.</a></li><li><a class="nounderline abstract_t">Galili U, Korkesh A, Kahane I, Rachmilewitz EA. Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells. Blood 1983; 61:1258.</a></li><li><a class="nounderline abstract_t">Yuan J, Kannan R, Shinar E, et al. Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes. Blood 1992; 79:3007.</a></li><li><a class="nounderline abstract_t">Wanachiwanawin W, Siripanyaphinyo U, Fucharoen S, et al. Activation of monocytes for the immune clearance of red cells in beta zero-thalassaemia/HbE. Br J Haematol 1993; 85:773.</a></li><li><a class="nounderline abstract_t">Chinprasertsuk S, Wanachiwanawin W, Pattanapanyasat K, et al. Relation of haemolytic anaemia and erythrocyte-bound IgG in alpha- and beta-thalassaemic syndromes. Eur J Haematol 1997; 58:86.</a></li><li><a class="nounderline abstract_t">Meliconi R, Uguccioni M, Lalli E, et al. Increased serum concentrations of tumour necrosis factor in beta thalassaemia: effect of bone marrow transplantation. J Clin Pathol 1992; 45:61.</a></li><li><a class="nounderline abstract_t">Wiener E, Wanachiwanawin W, Chinprasertsuk S, et al. Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassaemia syndromes: correlation with anaemia and monocyte activation. Eur J Haematol 1996; 57:364.</a></li><li><a class="nounderline abstract_t">Papassotiriou I, Traeger-Synodinos J, Kanavakis E, et al. Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease. J Pediatr Hematol Oncol 1998; 20:539.</a></li><li><a class="nounderline abstract_t">Rees DC, Williams TN, Maitland K, et al. Alpha thalassaemia is associated with increased soluble transferrin receptor levels. Br J Haematol 1998; 103:365.</a></li><li><a class="nounderline abstract_t">Adirojnanon P, Wasi P. Levels of haemoglobin H and proportions of red cells with inclusion bodies in the two types of haemoglobin H disease. Br J Haematol 1980; 46:507.</a></li><li><a class="nounderline abstract_t">Moura IC, Hermine O. Erythroferrone: the missing link in β-thalassemia? Blood 2015; 126:1974.</a></li><li><a class="nounderline abstract_t">Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46:678.</a></li><li><a class="nounderline abstract_t">Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood 2015; 126:2031.</a></li><li><a class="nounderline abstract_t">Piga A, Longo F, Duca L, et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009; 84:29.</a></li><li><a class="nounderline abstract_t">Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99:36.</a></li><li><a class="nounderline abstract_t">Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139:3.</a></li><li><a class="nounderline abstract_t">Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica 2013; 98:833.</a></li><li><a class="nounderline abstract_t">Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886.</a></li><li><a class="nounderline abstract_t">Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol 2002; 118:893.</a></li><li><a class="nounderline abstract_t">Hirsh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia. Br J Haematol 1966; 12:44.</a></li><li><a class="nounderline abstract_t">Hirsh J, McBride JA, Dacie JV. Thrombo-embolism and increased platelet adhesiveness in post-splenectomy thrombocytosis. Australas Ann Med 1966; 15:122.</a></li><li><a class="nounderline abstract_t">Mallat NS, Mallat SG, Musallam KM, Taher AT. Potential mechanisms for renal damage in beta-thalassemia. J Nephrol 2013; 26:821.</a></li><li><a class="nounderline abstract_t">Aliberti L, Gagliardi I, Gamberini MR, et al. Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria. Br J Haematol 2022; 198:903.</a></li><li><a class="nounderline abstract_t">Sanchez-Villalobos M, Blanquer M, Moraleda JM, et al. New Insights Into Pathophysiology of β-Thalassemia. Front Med (Lausanne) 2022; 9:880752.</a></li><li><a class="nounderline abstract_t">Cherchi GB, Pacifico L, Cossellu S, et al. Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr Infect Dis J 1995; 14:579.</a></li><li><a class="nounderline abstract_t">Adamkiewicz TV, Berkovitch M, Krishnan C, et al. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis 1998; 27:1362.</a></li><li><a class="nounderline abstract_t">Carniel E, Mazigh D, Mollaret HH. Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect Immun 1987; 55:277.</a></li><li><a class="nounderline abstract_t">Green NS. Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol 1992; 9:247.</a></li><li><a class="nounderline abstract_t">Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999; 111:278.</a></li><li><a class="nounderline abstract_t">Nagel RL. Innate resistance to malaria: the intraerythrocytic cycle. Blood Cells 1990; 16:321.</a></li><li><a class="nounderline abstract_t">Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744.</a></li><li><a class="nounderline abstract_t">Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383:522.</a></li><li><a class="nounderline abstract_t">Allen SJ, O'Donnell A, Alexander ND, et al. alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A 1997; 94:14736.</a></li><li><a class="nounderline abstract_t">Mockenhaupt FP, Ehrhardt S, Gellert S, et al. Alpha(+)-thalassemia protects African children from severe malaria. Blood 2004; 104:2003.</a></li><li><a class="nounderline abstract_t">Pattanapanyasat K, Yongvanitchit K, Tongtawe P, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood 1999; 93:3116.</a></li><li><a class="nounderline abstract_t">Pasvol G, Weatherall DJ, Wilson RJ. Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum. Nature 1977; 270:171.</a></li><li><a class="nounderline abstract_t">Shear HL, Grinberg L, Gilman J, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 1998; 92:2520.</a></li></ol></div><div id="topicVersionRevision">Topic 7090 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846925" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Is homozygous alpha-thalassaemia a lethal condition in the 1990s?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605609" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516118" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5326597" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hemoglobin H and the red cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13741593" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14192167" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : PROPERTIES OF HAEMOGLOBIN H AND THEIR SIGNIFICANCE IN RELATION TO FUNCTION OF HAEMOGLOBIN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6539334" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human hemoglobin Portland II (zeta 2 beta 2). Isolation and characterization of Portland hemoglobin components and their constituent globin chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14024862" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The abnormal haemoglobins in haemoglobin-H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : synthesis during erythroid cell maturation in alpha thalassemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Different types of alpha-thalassemia and significance of haemoglobin Bart's in neonates</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5332176" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thalassemia: the consequences of unbalanced hemoglobin synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13295661" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hemoglobin H; clinical, laboratory, and genetic studies of a family with a previously undescribed hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Description d'une nouvelle variétéd'anémie hémolytique congénitale</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954762" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Genetic and clinical features of hemoglobin H disease in Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415132" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The molecular basis for phenotypic variability of the common thalassaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089616" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hb E/beta-thalassaemia: a common&amp;clinically diverse disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7493679" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Globin chain turnover in reticulocytes from patients with beta (0) -thalassaemia/Hb E disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186524" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A scoring system for the classification of beta-thalassemia/Hb E disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519750" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hepcidin is suppressed by erythropoiesis in hemoglobin Eβ-thalassemia andβ-thalassemia trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486503" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dominantly Inherited beta-Thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13944958" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14080330" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : ALPHA-CHAIN OF HUMAN HEMOGLOBIN: OCCURRENCE IN VIVO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4370535" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ultrastructure of the inclusion bodies and nuclear abnormalities in beta-thalassemic erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943886" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943886" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4371697" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Denaturation of the normal and abnormal hemoglobin molecule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4305116" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4324898" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Studies on the stability of oxyhemoglobin A and its constituent chains and their derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173974" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3994972" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hemichrome binding to band 3: nucleation of Heinz bodies on the erythrocyte membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2985310" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086787" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in beta-thalassaemia intermedia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737089" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2211672" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Entrapment of purified alpha-hemoglobin chains in normal erythrocytes. A model for beta thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1581237" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Alpha- and beta-haemoglobin chain induced changes in normal erythrocyte deformability: comparison to beta thalassaemia intermedia and Hb H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7682576" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294111" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8219209" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1547347" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606558" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5765025" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805316" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of erythrocyte antioxidative enzyme activities between two types of haemoglobin H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652376" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Composition of the intra-erythroblastic precipitates in thalassaemia and congenital dyserythropoietic anaemia (CDA): identification of a new type of CDA with intra-erythroblastic precipitates not reacting with monoclonal antibodies to alpha- and beta-globin chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634456" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Abnormal assembly of membrane proteins in erythroid progenitors of patients with beta-thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3593963" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Erythrocyte membrane skeleton abnormalities in severe beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2521488" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579365" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The instability of the membrane skeleton in thalassemic red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2808414" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A study of membrane protein defects and alpha hemoglobin chains of red blood cells in human beta thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3595813" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Defective spectrin dimer self-association in thalassemic red cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2804358" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: implication for differences in clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759886" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Isolated beta-globin chains reproduce, in normal red cell membranes, the defective binding of spectrin to alpha-thalassaemic membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9057661" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The unusual pathobiology of hemoglobin constant spring red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6404113" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Different patterns of intraerythrocytic inclusion body distribution in the two types of haemoglobin H disease. An ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531618" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Membrane phospholipid asymmetry in human thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7214025" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rapid destruction of newly synthesized excess beta-globin chains in HbH disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359048" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The relationship between in vivo generated hemoglobin skeletal protein complex and increased red cell membrane rigidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728311" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mean corpuscular volume of heterozygotes for beta-thalassemia correlates with the severity of mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732017" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1585762" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Erythrocyte volume and haemoglobin concentration in haemoglobin H disease: discrimination between the two genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7327587" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Homozygous haemoglobin Constant Spring: a need for revision of concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233428" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Red cell deformability, splenic function and anaemia in thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14484764" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythrokinetics in thalassemia. II. Studies in Lepore trait and hemoglobin H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Studies of haemoglobin synthesis and red cell survival in haemoglobinopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001918" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4713633" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ultrastructural studies in -thalassaemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1201222" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Observations on the ultrastructure of erythropoietic cells and reticulum cells in the bone marrow of patients with homozygous beta-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6255979" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ultrastructural studies of erythropoiesis in beta-thalassaemia trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5968918" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Peptide analysis of the inclusions of erythroid cells in beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329696" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4908580" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ferrokinetics in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11071663" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26779615" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Novel players inβ-thalassemia dyserythropoiesis and new therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5640630" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intraerythroblastic instability of hemoglobin beta-4 (Hgb H).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6320861" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The fate of excess beta-globin chains within erythropoietic cells in alpha-thalassaemia 2 trait, alpha-thalassaemia 1 trait, haemoglobin H disease and haemoglobin Q-H disease: an electron microscope study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : rogrammed cell death (PCD) and ineffective erythropoiesis in Cooley's anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The role of iron overload in the extent of programmed cell death (PCD) in patients with Cooley's anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156257" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : HSP70 sequestration by freeα-globin promotes ineffective erythropoiesis inβ-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21702968" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Phosphoproteomic analysis of apoptotic hematopoietic stem cells from hemoglobin E/β-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12031913" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Enhanced macrophagic attack on beta-thalassemia major erythroid precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259854" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Erythroblast- and erythrocyte-bound antibodies in alpha and beta thalassaemia syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4183531" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The correlation between red-cell survival and excess of alpha-globin synthesis in beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14260170" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : THE METABOLISM OF THE INDIVIDUAL C14 LABELED HEMOGLOBINS IN PATIENTS WITH H-THALASSEMIA, WITH OBSERVATIONS ON RADIOCHROMATE BINDING TO THE HEMOGLOBINS DURING RED CELL SURVIVAL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3886235" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Erythrocyte membrane alterations in beta-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/508634" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Phagocytosis of nucleated and mature beta thalassaemic red blood cells by mouse macrophages in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3186707" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8342566" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6839023" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586745" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918042" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Activation of monocytes for the immune clearance of red cells in beta zero-thalassaemia/HbE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111588" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Relation of haemolytic anaemia and erythrocyte-bound IgG in alpha- and beta-thalassaemic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740519" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Increased serum concentrations of tumour necrosis factor in beta thalassaemia: effect of bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9003477" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassaemia syndromes: correlation with anaemia and monocyte activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856674" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827906" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Alpha thalassaemia is associated with increased soluble transferrin receptor levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6255980" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Levels of haemoglobin H and proportions of red cells with inclusion bodies in the two types of haemoglobin H disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26494918" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Erythroferrone: the missing link inβ-thalassemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880340" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Identification of erythroferrone as an erythroid regulator of iron metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26276665" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model ofβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006228" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : High nontransferrin bound iron levels and heart disease in thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756150" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The hypercoagulable state in thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17854302" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23729725" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Non-transfusion-dependent thalassemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032507" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181063" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5906268" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5924571" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Thrombo-embolism and increased platelet adhesiveness in post-splenectomy thrombocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475461" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Potential mechanisms for renal damage in beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35768889" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Beta-thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35492364" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : New Insights Into Pathophysiology ofβ-Thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567285" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Prospective study of Yersinia enterocolitica infection in thalassemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9868642" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3793233" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Expression of iron-regulated proteins in Yersinia species and their relation to virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1525003" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417734" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Thalassemia and malaria: new insights into an old problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2257317" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Innate resistance to malaria: the intraerythrocytic cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3713863" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : High frequencies of alpha-thalassaemia are the result of natural selection by malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849722" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : High incidence of malaria in alpha-thalassaemic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9405682" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : alpha+-Thalassemia protects children against disease caused by other infections as well as malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198952" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Alpha(+)-thalassemia protects African children from severe malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10216109" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/337159" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of foetal haemoglobin on susceptibility of red cells to Plasmodium falciparum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746793" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
